Sudeep Thapa
West End, NCNPI 1184966624
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by UCB, Inc. at 32.1% of the total. 2025 is the largest year on record at $13,742, 6.3 times the $2,187 reported in 2019.
Across 570 payments — averaging $55.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$10K
- GSK$7K
- AbbVie$4K
- Amgen$3K
- Progentec Diagnostics, Inc.$2K
- Pfizer$845
- plus $4K from 21 others
What the payments were for
- Consulting fees$15,74350%
- Travel & lodging$2,5688%
- Food & beverage$13,07742%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 29 | $10,090 |
| GSK | 37 | $7,283 |
| AbbVie | 110 | $3,832 |
| Amgen(2 entities) | 145 | $2,813 |
| Progentec Diagnostics, Inc. | 1 | $2,400 |
| Pfizer | 71 | $845 |
| Lilly USA, LLC | 36 | $780 |
| AstraZeneca(2 entities) | 21 | $697 |
| Johnson & Johnson | 30 | $635 |
| E.r. Squibb & Sons, L.L.C. | 25 | $599 |
| Novartis | 15 | $401 |
| Genentech USA, Inc. | 10 | $262 |
| Radius Health, Inc. | 6 | $116 |
| Mallinckrodt Hospital Products Inc. | 5 | $92 |
| Sobi, Inc | 4 | $88 |
| Aurinia Pharma U.S., Inc. | 4 | $85 |
| Sanofi | 4 | $84 |
| Boehringer Ingelheim | 4 | $81 |
| Fresenius Kabi USA, LLC | 3 | $58 |
| Bristol Myers Squibb | 2 | $53 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| Sandoz | 1 | $32 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Bioventus LLC | 1 | $21 |
| Organon | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 175 | $1,349,512 |
| Humira(Cf) PenAdalimumab | 99 | $750,079 |
| RinvoqUpadacitinib | 98 | $685,845 |
| Xeljanz XrTofacitinib Citrate | 70 | $461,478 |
| Orencia ClickjectAbatacept | 63 | $375,195 |
| TremfyaGuselkumab | 20 | $291,689 |
| Actemra ActpenTocilizumab | 47 | $197,844 |
| OtezlaApremilast | 40 | $194,944 |
| TavneosAvacopan | 12 | $191,423 |
| OrenciaAbatacept | 28 | $164,330 |
| Taltz AutoinjectorIxekizumab | 13 | $92,541 |
| BenlystaBelimumab | 15 | $69,509 |
| Hydroxychloroquine Sulfate | 1,106 | $56,381 |
| KevzaraSarilumab | 13 | $55,634 |
| Leflunomide | 554 | $31,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $3,832 | $685,84598 claims |
| AmgenOtezla, Tavneos | $2,813 | $386,36752 claims |
| Johnson & JohnsonTremfya | $635 | $291,68920 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $599 | $164,33028 claims |
| GSKBenlysta | $7,283 | $69,50915 claims |
| SanofiKevzara | $84 | $55,63413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.